An eight-month clinical study of LA-2575 30.0 mg: a new 4-month, subcutaneous delivery system for leuprolide acetate in the treatment of prostate cancer

By Sartor O.   Dineen M.K.   Perez-Marreno R.   Chu F.M.   Carron G.J.   Tyler R.C.  

Urology, Vol. 62, Iss. 2, 2003-08 ,pp. : 319-323

Elsevier

Access to resources Recommend Favorite

Evaluation of an implant that delivers leuprolide for 1 year for the palliative treatment of prostate cancer

By Fowler J.E.   Flanagan M.   Gleason D.M.   Klimberg I.W.   Gottesman J.E.   Sharifi R.  

Urology, Vol. 55, Iss. 5, 2000-05 ,pp. : 639-642

Elsevier

Access to resources Recommend Favorite

A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer 2

By McLeod D.   Zinner N.   Tomera K.   Gleason D.   Fotheringham N.   Campion M.   Garnick M.B.   for the Abarelix Study Group  

Urology, Vol. 58, Iss. 5, 2001-11 ,pp. : 756-761

Elsevier

Access to resources Recommend Favorite

Liarozole-a novel treatment approach for advanced prostate cancer: results of a large randomized trial versus cyproterone acetate - results from 2 European Organization for Research on Treatment of Cancer trials

By Debruyne F.J.M.   Murray R.   Fradet Y.   Johansson J.E.   Tyrrell C.   Boccardo F.   Denis L.   Marberger J.M.   Brune D.   Rassweiler J.   Vangeneugden T.   Bruynseels J.   Janssens M.   De Porre P.  

Urology, Vol. 52, Iss. 1, 1998-07 ,pp. : 72-81

Elsevier

Access to resources Recommend Favorite

Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study

By Higano C.S.   Ellis W.   Russell K.   Lange P.H.  

Urology, Vol. 48, Iss. 5, 1996-11 ,pp. : 800-804

Elsevier

Access to resources Recommend Favorite